References
1. Liu R, et al. Cost Effectiveness of Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (Rr Lbcl) in the US. 25th Congress of the European Haematology Association : abstr. EP1731, 11 Jun 2020. Available from: URL: https://library.ehaweb.org/eha/2020/eha25th/294211/julia.thornton.snide.cost.effectiveness.of.axicabtagene.ciloleucel.28axi-cel29.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1766%2Aot_id%3D23248%2Afeatured%3D16775
2. Sierra J, et al. Axicabtagene Ciloleucel for the Management of Patients with Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: an Economic Evaluation for Spain. 25th Congress of the European Haematology Association : abstr. EP1763, 11 Jun 2020. Available from: URL: https://library.ehaweb.org/eha/2020/eha25th/294243/maria.presa.axicabtagene.ciloleucel.for.the.management.of.patients.with.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1766%2Aot_id%3D23248%2Afeatured%3D16775
Rights and permissions
About this article
Cite this article
Axicabtagene ciloleucel good value in B-cell lymphoma. PharmacoEcon Outcomes News 858, 2 (2020). https://doi.org/10.1007/s40274-020-6975-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6975-2